Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

Molecular Cancer Research publishes articles featuring novel, basic cancer research discoveries that prioritize broad molecular and cellular processes. Areas of emphasis include cell cycle and ...

BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving ... AstraZeneca, Amgen, BioNTech, Eisai, GSK, ...

Head and Neck Cancer Pipeline Outlook Key Takeaways from the Head and ... QBiotics Group Limited, Memgen, Inc., BioNTech, ...

ATHENA-COMBO investigators enrolled patients with newly diagnosed stage III/IV ovarian cancer at 294 sites in 24 countries ... Novartis, Corcept, BioNTech, Genmab, DFG, DKH, and Seagen.

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit ...

The revamped vaccine is an effort by regulators and vaccine makers to keep pace with the virus, which continues to evolve ...

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...